Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia.

Unfortunately, only one patient sample was available, and more patient samples need to be verified in the future. All patients had the T315I mutation alone or compound mutation when relapsed before VPD regimen treatment, including 15 patients with the T315I mutation alone and 4 with compound kinase mutations (100% T315I + 50% E255K/V, 100% T315I + 100% E279K, 100% T315I + 100% Y253H, and 54% G250E + 36% F359V for each). For post-remission treatment, 6 patients who attained CMR directly received allo-HSCT, and the remaining 11 patients continued to receive the VPD regimen. Of the 6 patients who received allo-HSCT, 2/6 (patient 1 and patient 19) received 45 mg of ponatinib per day as maintenance treatment, and 4 other patients did not receive maintenance treatment. [Extracted from the article]